Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cancer
Wilbur A. Franklin, Jerry Haney, Michio Sugita et al. · 2010
Cited by 1 works.
Authors
References
- Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
- Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- Detection of PCR products using self-probing amplicons and fluorescence
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas